Alliances
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that ModernaTX, Inc. has exercised its option to enter into an exclusive licensing agreement with respect to certain Affimers against a potential therapeutic target that has been part of an ongoing research collaboration between the two companies.
The area is home to numerous well-known players in the pharma industry, including Abbott, Iovance, Gossamer Bio, Crown Biosciences, Illumina, Human Longevity and many, many more.
The two Phase III trials are part of a five-trial package the companies are conducting to support potential regulatory approval for this indication.
Eisai Co. and Purdue Pharma presented data at the Sleep Research Society’s Conference regarding their lemborexant for the treatment of insomnia. The meeting was held in Clearwater Beach, Florida.
Janssen Pharmaceutical, a Johnson & Johnson company, inked a worldwide collaboration and license deal with MeiraGTx to develop, manufacture and commercialize a portfolio of drugs for inherited retinal diseases.
Shares of Fortress Biotech have skyrocketed more than 62 percent in premarket trading after its subsidiary Caelum Biosciences forged a deal worth up to more than $500 million with Alexion Pharmaceuticals.
It’s no secret that the global biopharma and life sciences industry is large. Sometimes the immense size of the industry can lead fascinating news tidbits to fall through the cracks, particularly those from smaller companies scattered across the globe. This week BioSpace will launch a new roundup of news from companies across the globe.
Under terms of the agreement, Neurocrine provided Voyager with $165 million in an upfront payment, along with funding for ongoing development of each program. If developmental, regulatory and commercial milestones are hit, Voyager could snag up to $1.7 billion.
Celgene has struck another collaborative deal, even as the large pharmaceutical company is in the process of being folded into the operations of its new owner, Bristol-Myers Squibb. Under terms of the deal, Celgene will pay Triphase $40 million in upfront funding. Celgene can then pay up to an additional $940 million if certain milestones are hit.
Pfizer and Eli Lilly and Co. announced that their tanezumab hit two out of three co-primary endpoints in one dose and all three with a higher dose in patients with moderate-to-severe osteoarthritis (OA) pain in a Phase III trial.
PRESS RELEASES